Stocks to Watch Tomorrow —>> Tuesday delivered the market’s most important positive surprise in months — June CPI came in at 3.5% annually versus the 3.8% forecast, and core inflation flat-lined at 0.0% month-over-month, the coolest core reading since 2021. The Nasdaq jumped 0.90% to 26,107.01, tech stocks led, and the probability of a July Fed rate hike crashed from 42% to just 14%.

Wednesday tests whether Tuesday’s relief was the start of a trend or a one-month anomaly. The June Producer Price Index (PPI) arrives at 8:30 AM — the upstream inflation read that tells us what’s coming for consumers 3–6 months from now. Kevin Warsh takes his testimony to the Senate Banking Committee for Day 2. And a wall of earnings — J.B. Hunt, United Airlines, Morgan Stanley, J&J, Elevance Health, ASML, Cintas, and more — print before the open or overnight.

Here are 10 stocks to have on your screen.

📊 Today’s Close — The Setup Heading Into Wednesday

🔑 WEDNESDAY’S MACRO ANCHOR: PPI (June) at 8:30 AM ET

After Tuesday’s CPI bonanza, PPI is the confirmation test.

• Prior MoM PPI: +1.1% (May) — dangerously elevated at the production level
• Prior YoY PPI: +6.5% — well above historical norms
• The question: Did the same energy price decline that dragged CPI lower in June also flow through to producer prices?
• If PPI follows CPI lower (say, below +4% YoY): confirmation that the inflation reversal is broad-based and structural; rate hike bets fall further; growth stocks extend Tuesday’s rally
• If PPI stays stubbornly above +5.5% YoY: suggests input costs for producers are still hot despite energy relief; raises concern that CPI will rebound in August and September; gives Warsh cover to hint at a September hike

Warsh Day 2 — Senate Banking Committee (10:00 AM ET): After Tuesday’s House testimony where Warsh said he wasn’t ready to “declare victory” on inflation despite the softer CPI print, Wednesday’s Senate session will probe him further. Watch for any specific language on the September rate decision — senators will ask directly.

🚚 1. J.B. Hunt Transport Services (NASDAQ: JBHT) — The Freight Market’s Verdict on Consumer Demand

Reports: Wednesday Before Open | Sector: Intermodal Logistics | Signal: Consumer Health

In every earnings cycle, one name tells the truth about the real economy before retail sales data does. J.B. Hunt is that name. The largest intermodal carrier in North America, J.B. Hunt’s volume data is a real-time proxy for consumer goods demand, manufacturing inventory restocking, and e-commerce fulfillment velocity.

Why Wednesday’s print is especially meaningful:

• Tuesday’s softer CPI creates a “soft landing” narrative — JBHT’s freight volumes will confirm or deny whether that narrative has legs in the actual goods-movement economy
• IBM’s Q2 miss (clients shifted capex away from software toward hardware) could accelerate demand for domestic freight as server and memory shipments increase
• J.B. Hunt’s intermodal volume is the leading indicator; truckload pricing tells you if supply chain balance is returning
• Watch for: any forward guidance language on H2 2026 freight market conditions — if JBHT sounds optimistic, it’s a green light for consumer discretionary and retail stocks through earnings season

✈️ 2. United Airlines (NASDAQ: UAL) — The Oil and CPI Intersection

Reports: Wednesday Before Open | Sector: Airlines | Oil: Above $80/barrel

United Airlines reports Wednesday in an environment where two competing forces are pulling its stock in opposite directions:

• Bullish: Tuesday’s softer CPI (3.5%) reduces consumer spending pressure, supporting leisure travel demand; airline ticket pricing has remained strong
• Bearish: Oil above $80/barrel (after Monday’s Iranian blockade news pushed crude +8.78%) raises fuel costs; United guided Q2 fuel costs +$2B year-over-year coming into the quarter

The critical numbers to watch:

• Q2 revenue vs. estimate — is premium travel holding up?
• Q3 fuel cost guidance — this is the make-or-break figure given oil’s volatility
• Load factor data — are planes full or partially empty?
• Management commentary on Iran/Hormuz impact on international routes

🔬 3. ASML (NASDAQ: ASML) — The One Earnings Print That Validates or Destroys the AI Chip Capex Story

Reports: Wednesday (European market open, pre-US open) | Sector: Semiconductor Equipment

ASML makes the extreme ultraviolet (EUV) lithography machines that every advanced chipmaker on Earth requires. Without an ASML EUV system, there is no 3nm chip, no 2nm chip, no next-generation HBM memory. This makes ASML’s quarterly new order bookings the single most reliable forward indicator of AI chip capex commitments 12–24 months ahead.

Why Wednesday’s ASML report matters to the whole sector:

• After IBM’s CEO confirmed clients are aggressively shifting capex toward hardware and memory — validating the AI infrastructure buildout — ASML’s orders should reflect that same demand surge
• A strong ASML order book validates the chip sector’s July rebound (after a brutal 20%+ selloff from peak)
• A weak or declining order book would signal chipmakers are pulling back on future capacity commitments — a bearish signal that could re-extend the semiconductor correction
• ASML has beaten earnings estimates in each of the past three quarters

Analyst expectations: ASML is expected to show continued strong demand from TSMC, Samsung, and Intel for advanced process capacity. Any upward revision to its 2026/2027 order guidance would be a sector-level catalyst.

🧬 4. Sagimet Biosciences (NASDAQ: SGMT) — The Off-the-Radar Biotech at Leerink’s Forum Wednesday

Sector: Biotech / MASH / Dermatology | Event: Leerink Partners Therapeutics Forum (Boston) | July 15

Sagimet is one of the most under-the-radar names on the entire 2026 watchlist — and one of the most asymmetric setups heading into Wednesday. The company has a dual-indication asset (denifanstat) targeting both MASH (metabolic-associated steatohepatitis) and acne vulgaris with an FDA Breakthrough designation — and it’s presenting to investors and analysts at the Leerink Partners Therapeutics Forum on July 15 with one-on-one meetings.

Why Wednesday specifically matters:

• Sagimet “moves hard on incremental commentary” according to veteran biotech analyst The M&A Hunter, making the Leerink forum one of the most catalyst-rich events for a micro-cap biotech this week
• The company raised $175 million in April 2026 — giving it a cash runway well into 2028 with no near-term dilution risk
• Phase 3 U.S. acne trial is expected to begin in H2 2026 — one of the potential topics at Wednesday’s forum
• The MASH indication (formerly NASH) comes directly after Madrigal’s Rezdiffra (resmetirom) blockbuster success — the market is actively looking for the next MASH winner
• Any update on partnership discussions or clinical data timelines will be the catalyst

M&A angle: Sagimet’s dual-indication asset with Breakthrough designation makes it a plausible acquisition target for larger pharma players looking for MASH or dermatology pipeline exposure.

🏥 5. Elevance Health (NYSE: ELV) — Health Insurance After Today’s -1.93% Sector Selloff

Reports: Wednesday Before Open | Sector: Health Insurance | Context: XLV -1.93% today

The healthcare sector was Tuesday’s worst performer at -1.93% — partially rotation out of defensives as tech revived on CPI news. Elevance Health’s Wednesday earnings will reset the narrative for the entire managed care sector.

Key watch:

• Medical cost ratio (MCR) — the health insurer’s equivalent of a gross margin; if MCR is rising, medical costs are outpacing premium revenue
• Medicaid and Medicare Advantage enrollment trends — government program mix is the key swing factor for Elevance’s 2026 financials
• Guidance for full-year 2026 — any trim here cascades through HUM, CI, CVS, and UNH (which reports Thursday)
• Elevance recently announced layoffs and restructuring — cost-cutting is the counterweight to MCR pressure

🏦 6. Morgan Stanley (NYSE: MS) — Following the Goldman Trail

Reports: Wednesday Before Open | Sector: Investment Banking / Wealth Management

Morgan Stanley reports Wednesday morning following Tuesday’s Goldman Sachs print. The key theme across major investment banks this quarter: M&A deal flow is recovering, and market-making revenue surged on volatility. Both factors benefit Morgan Stanley disproportionately.

Specific watches:

• Investment management AUM growth — the stock market’s +9.5% H1 2026 performance drives fee revenue without adding costs
• Wealth management net new assets — the key competitive metric vs. Merrill Lynch and UBS
• Investment banking pipeline — the post-Iran ceasefire period saw a pause in deal-making; is the pipeline building for H2?
• Any comments on the 30Y Treasury at 5.1% — the highest level since before the 2008 financial crisis — and its impact on fixed income trading revenue

🏦 7. M&T Bank (NYSE: MTB) — The Regional Bank Worth Watching Wednesday

Reports: Wednesday Before Open | Sector: Regional Banking | Market: Northeast US

M&T Bank is a Buffalo, NY-based regional bank that serves as one of the better proxies for Northeast U.S. commercial real estate conditions — an area of significant concern given elevated long-term rates. M&T has deep exposure to commercial real estate lending, and Wednesday’s report will tell investors whether CRE stress is materializing or manageable.

What to watch:

• CRE loan quality metrics (non-performing loans, charge-offs)
• Net interest margin trajectory — have deposit costs peaked?
• Any reserve building for CRE losses — a leading indicator of future charge-offs

🏥 8. Johnson & Johnson (NYSE: JNJ) — The Med-Tech and Pharma Bellwether

Reports: Wednesday Before Open | Sector: Diversified Healthcare

J&J is one of the most stable, cash-generative companies in the S&P 500 — and its Wednesday report carries weight across both the pharmaceutical and medical device sectors. The company is now focused on two major growth drivers: its pharmaceutical pipeline (Darzalex for multiple myeloma, Tremfya for IBD) and its MedTech division (Abiomed heart pumps, orthopedics).

Key catalysts:

• Any update on the talc litigation resolution (decades-long cancer lawsuit settlement)
• MedTech segment volume — surgical procedure volumes are a key indicator of hospital system health
• Pharmaceutical pipeline guidance — any Darzalex revenue upside surprise would be notable

🏭 9. Cintas (NASDAQ: CTAS) — The Employment Indicator Nobody Talks About

Reports: Wednesday Before Open | Sector: Uniform Services / Workforce Solutions

Cintas is a fascinating employment barometer: the company rents and services uniforms to businesses, which means its customer count and revenue per customer directly track active employment in the U.S. economy. When companies hire, Cintas adds new uniform accounts. When companies fire, it loses them. It’s the most real-time private-sector employment indicator in the earnings season.

Why Wednesday’s print matters post-CPI:

• Tuesday’s softer inflation read increases confidence in a soft landing scenario — Cintas’s employment data will confirm or deny
• ISM Services Employment Index expanded in June for the first time in 4 months — Cintas should confirm this trend
• Cintas has beaten earnings estimates consistently and often raises guidance; any tone change would be notable

🪨 10. Alcoa (NYSE: AA) — The AI Infrastructure Materials Play After Close

Reports: Wednesday After Close | Sector: Aluminum / Materials | AI Data Center Angle

Alcoa reports Wednesday evening — and it’s one of the more interesting earnings reports to watch for AI infrastructure implications. Aluminum is a critical material in server rack manufacturing, cable production, and data center cooling systems. As the AI buildout accelerates, aluminum demand for tech infrastructure is a growing revenue driver for Alcoa beyond its traditional auto and aerospace customers.

Key catalysts:

• Aluminum pricing — has the Iran-driven energy cost increase (aluminum smelting is highly energy-intensive) been offset by higher aluminum prices?
• Any data center/AI infrastructure customer revenue commentary
• 2026 volume guidance — a beat here would be a read-through for the broader materials sector

📅 Wednesday’s Full Calendar

Follow TNN for daily stock market news and financial news today.

Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss. Always complete independent due diligence prior to executing equity trades. Prices referenced reflect July 14, 2026 closing conditions. Earnings releases and economic data can cause sudden, sharp market moves in either direction. Past performance is not indicative of future results.

Further Reading:

About The Author

Kasia Davis

See author's posts